734 related articles for article (PubMed ID: 28278077)
21. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
22. Endothelium-Dependent Induction of Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cells Is Inhibited by Calcitriol and Curcumin.
Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; García-Becerra R; Zentella-Dehesa A; Larrea F; Díaz L
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887002
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia induced epithelial-mesenchymal transition and vasculogenic mimicry formation by promoting Bcl-2/Twist1 cooperation.
Liu K; Sun B; Zhao X; Wang X; Li Y; Qiu Z; Gu Q; Dong X; Zhang Y; Wang Y; Zhao N
Exp Mol Pathol; 2015 Oct; 99(2):383-91. PubMed ID: 26318343
[TBL] [Abstract][Full Text] [Related]
24. Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.
Mao Y; Zhu L; Huang Z; Luo C; Zhou T; Li L; Wang G; Yang Z; Qi W; Yang X; Gao G
Endocr Relat Cancer; 2020 Jan; 27(1):23-39. PubMed ID: 31705798
[TBL] [Abstract][Full Text] [Related]
25. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of transgelin blocks interleukin-8 utilization and suppresses vasculogenic mimicry in breast cancer cells.
Aikins AR; Kim M; Raymundo B; Kim CW
Exp Biol Med (Maywood); 2017 Mar; 242(6):573-583. PubMed ID: 28058861
[TBL] [Abstract][Full Text] [Related]
27. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
28. S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.
Liu S; Ni C; Zhang D; Sun H; Dong X; Che N; Liang X; Chen C; Liu F; Bai J; Lin X; Zhao X; Sun B
Cell Death Dis; 2019 Feb; 10(3):200. PubMed ID: 30814488
[TBL] [Abstract][Full Text] [Related]
29. LIFU/MMP-2 dual-responsive release of repurposed drug disulfiram from nanodroplets for inhibiting vasculogenic mimicry and lung metastasis in triple-negative breast cancer.
Liu Y; Tang R; Cao Y; Wu N; Qin Q; Chen Y; Wei X; Ren J; Sun Y; Zhou H; Zhou Y; Li P
J Nanobiotechnology; 2024 Apr; 22(1):209. PubMed ID: 38664830
[TBL] [Abstract][Full Text] [Related]
30. TP53INP1 inhibits hypoxia-induced vasculogenic mimicry formation via the ROS/snail signalling axis in breast cancer.
Wang Y; Sun H; Zhang D; Fan D; Zhang Y; Dong X; Liu S; Yang Z; Ni C; Li Y; Liu F; Zhao X
J Cell Mol Med; 2018 Jul; 22(7):3475-3488. PubMed ID: 29655255
[TBL] [Abstract][Full Text] [Related]
31. Subpopulations of uPAR+ contribute to vasculogenic mimicry and metastasis in large cell lung cancer.
Li Y; Sun B; Zhao X; Zhang D; Wang X; Zhu D; Yang Z; Qiu Z; Ban X
Exp Mol Pathol; 2015 Apr; 98(2):136-44. PubMed ID: 25661888
[TBL] [Abstract][Full Text] [Related]
32. miR-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: an essential role for Twist-1 in HCC.
Zhao N; Sun H; Sun B; Zhu D; Zhao X; Wang Y; Gu Q; Dong X; Liu F; Zhang Y; Li X
Sci Rep; 2016 Mar; 6():23091. PubMed ID: 26980408
[TBL] [Abstract][Full Text] [Related]
33. Effect of grape seed proanthocyanidins on tumor vasculogenic mimicry in human triple-negative breast cancer cells.
Luan YY; Liu ZM; Zhong JY; Yao RY; Yu HS
Asian Pac J Cancer Prev; 2015; 16(2):531-5. PubMed ID: 25684483
[TBL] [Abstract][Full Text] [Related]
34. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE‑cadherin/EphA2/MMP9/MMP2 expression.
Guo JQ; Zheng QH; Chen H; Chen L; Xu JB; Chen MY; Lu D; Wang ZH; Tong HF; Lin S
Int J Oncol; 2014 Sep; 45(3):1065-72. PubMed ID: 24938458
[TBL] [Abstract][Full Text] [Related]
35. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
[TBL] [Abstract][Full Text] [Related]
36. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
37. Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes.
Han H; Du L; Cao Z; Zhang B; Zhou Q
Eur J Pharmacol; 2018 Jan; 818():593-603. PubMed ID: 29162433
[TBL] [Abstract][Full Text] [Related]
38. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
Shi JF; Sun MG; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
J Biomed Nanotechnol; 2015 Sep; 11(9):1568-82. PubMed ID: 26485927
[TBL] [Abstract][Full Text] [Related]
39. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
[TBL] [Abstract][Full Text] [Related]
40. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
